Using the SWEET tool to predict how long an ERCP will take
Official title: Prospective Validation of the SWEET Tool for Pre-diction of Preintervention ERCP Procedure Time.
Run by Universitair Ziekenhuis Brussel · NCT07259395 · Data updated 2026-11-12
This project will test whether the SWEET tool can accurately predict how long an ERCP will take for adult patients having first-time or repeat ERCPs.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 363 (estimated) |
| Sponsor | Universitair Ziekenhuis Brussel Academic / other |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | December 2025 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | December 2, 2025 |
| Trial ID | NCT07259395 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults older than 18 scheduled for intraductal ERCP at UZ Brussel, including both first-time and repeat procedures and cases performed by fellows under supervision.
✕Probably not a fit
Patients with surgically altered anatomy or ERCPs combined with therapeutic EUS interventions are excluded and would not benefit from this validation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational validation will compare preprocedure SWEET tool estimates to the actual measured durations of ERCPs performed at UZ Brussel. The SWEET tool was derived from a large Swedish registry and uses ten patient- and procedure-related variables to estimate procedure time; here it will be applied to adults undergoing intraductal ERCP, including procedures performed by fellows under supervision. ERCPs in altered anatomy and those combined with therapeutic EUS are excluded from this validation. The primary outcome is the accuracy of the predicted times compared with observed times, reported with standard metrics such as RMSE.
Why it matters
Potential benefit: If successful, the SWEET tool could help clinics schedule ERCPs more accurately, reduce delays and overtime, and improve patient flow.
How similar studies have gone: A large retrospective derivation using 74,248 ERCPs in the Swedish GallRiks registry produced the SWEET tool with promising predictive performance, but prospective validation has been limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * First or redo-ERCP * Intraductal endoscopy * ERCPs performed by fellows under supervision Exclusion Criteria: * ERCPs in altered anatomy * ERCPs combined with therapeutic EUS interventions
Where it's running
-
UZ Brussel
Brussels, Belgium Recruiting
Study contacts
- Study coordinator: Helena Degroote, MD, PhD
- Email: helena.degroote@uzbrussel.be
- Phone: +32 2 477 68 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Electronic bidets after anal surgery vs water rinsing
A small study tests whether using an electronic bidet after anal fistula or hemorrhoid surgery helps patients more than standard water rinsing.
-
Drug-induced Crystalluria and Kidney Injury in Hospitalized Patients on Sulfamethoxazole, High-Dose Ciprofloxacin, or High-Dose Amoxicillin
This study tests whether hospitalized adults taking high-dose sulfamethoxazole, ciprofloxacin, or IV amoxicillin develop urinary crystals and how that relates to acute kidney injury.
-
Home or Hospital Intrathecal Pump Refills: A Patient Trial
This study tests whether refilling an implanted intrathecal pump at home is as safe and comfortable as refilling it in the hospital for adults with chronic pain or severe spasticity.
-
Anatomy-Based Fitting for People with a Cochlear Implant and Hearing Aid
This study tests whether an anatomy-based frequency distribution works better than the default one for adults with a cochlear implant and a contralateral hearing aid.
-
Intrathecal drug delivery vs standard care for severe cancer pain
This trial tests whether delivering pain medicine directly into the spinal fluid helps people with severe cancer pain experience better relief than usual oral medications.
-
One-dose pembrolizumab before surgery for high-risk localized melanoma
This trial gives one dose of pembrolizumab six weeks before surgery to see if it helps adults with high‑risk melanoma that appears confined on scans.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.